Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab

1. Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: A review. J Family Med Prim Care. 2020; 9 (1): 20-24.10.4103/jfmpc.jfmpc_689_19 Search in Google Scholar

2. Rønholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017; 18 (11): 2297.10.3390/ijms18112297 Search in Google Scholar

3. Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021; 184 (1): 14-24.10.1111/bjd.19380 Search in Google Scholar

4. Tampa M, Caruntu C, Mitran M, Mitran C, Sarbu I, Rusu LC, et al. Markers of Oral Lichen Planus Malignant Transformation. Dis Markers. 2018; 2018:1959506.10.1155/2018/1959506 Search in Google Scholar

5. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin- 17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160 (2): 319-24.10.1111/j.1365-2133.2008.08902.x Search in Google Scholar

6. Gaffen, Sarah L. Structure and signalling in the IL-17 receptor family. Nature reviews. Immunology vol. 9,8 (2009): 556-67.10.1038/nri2586 Search in Google Scholar

7. Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130 (1): 145-54.e9.10.1016/j.jaci.2012.04.024 Search in Google Scholar

8. Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018; 9:1682.10.3389/fimmu.2018.01682 Search in Google Scholar

9. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386 (9999): 1137-1146.10.1016/S0140-6736(15)61134-5 Search in Google Scholar

10. Spindeldreher S, Maillère B, Correia E, Tenon M, Karle A, Jarvis P, et al. Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatol Ther (Heidelb). 2018; 8 (1): 57-68.10.1007/s13555-018-0220-y582532529392570 Search in Google Scholar

11. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168 (2): 402-11.10.1111/bjd.12070 Search in Google Scholar

12. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014; 371 (4): 326-338.10.1056/NEJMoa1314258 Search in Google Scholar

13. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebocontrolled, phase 3 study. The Journal of dermatology. 2014; 41 (12): 1039–1046.10.1111/1346-8138.12668 Search in Google Scholar

14. Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015; 75 (3): 329-38.10.1007/s40265-015-0359-0 Search in Google Scholar

15. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021; 35 (4): 938-947.10.1111/jdv.17002 Search in Google Scholar

16. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/ pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015; 29(6):1082-1090.10.1111/jdv.12751 Search in Google Scholar

17. Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018; 35 (2): 135-144.10.1007/s40266-018-0520-z Search in Google Scholar

18. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderateto-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394 (10201): 831-839.10.1016/S0140-6736(19)31773-8 Search in Google Scholar

19. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. J Am Acad Dermatol. 2019; 80 (5): 1344-1352.10.1016/j.jaad.2019.01.06630716404 Search in Google Scholar

20. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021; 184 (1): 50-59.10.1111/bjd.19341798395432594522 Search in Google Scholar

21. Wu NL, Hsu CJ, Sun FJ, Tsai TF. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study. J Dermatol. 2017; 44 (10): 1129-1137.10.1111/1346-8138.13900 Search in Google Scholar

22. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017; 177 (1): 47-62.10.1111/bjd.15015 Search in Google Scholar

23. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375 (4): 345-356.10.1056/NEJMoa1512711 Search in Google Scholar

24. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016; 15 (10): 1413-20.10.1080/14740338.2016.1221923 Search in Google Scholar

25. Reich K, Warren RB, Coates LC, Di Comite G. Longterm efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1161-1173.10.1111/jdv.16124 Search in Google Scholar

26. Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014; 105 Suppl 1: 34-40.10.1016/S0001-7310(14)70016-X Search in Google Scholar

27. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011; 332 (6025): 65-68.10.1126/science.1200439307004221350122 Search in Google Scholar

28. Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol. 2016; 12 (1): 1-4.10.1586/1744666X.2016.111273926561053 Search in Google Scholar

29. Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019; 19 (1): 45-54.10.1080/14712598.2019.155523530500317 Search in Google Scholar

30. Eppinga H, Poortinga S, Thio HB, et al. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23 (10): 1783-1789.10.1097/MIB.000000000000116928617755 Search in Google Scholar

31. Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study. J Invest Dermatol. 2019; 139 (2): 316-323.10.1016/j.jid.2018.07.029 Search in Google Scholar

32. van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016; 75 (1): 83-98.e4.10.1016/j.jaad.2016.03.024 Search in Google Scholar

33. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018; 77 (6): 890-897.10.1136/annrheumdis-2017-212687 Search in Google Scholar

34. Fujita H, Ohtsuki M, Morita A, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. J Dermatol. 2021; 48 (2): 175-183.10.1111/1346-8138.15655 Search in Google Scholar

35. Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015; 11: 1767-77.10.2147/TCRM.S79053 Search in Google Scholar

36. Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O’Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020; 9: 2020-2-1.10.7573/dic.2020-2-1 Search in Google Scholar

37. Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res. 2006; 34 (3): 229-42.10.1385/IR:34:3:229 Search in Google Scholar

38. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2 (2): e000062.10.1161/JAHA.113.000062364727823557749 Search in Google Scholar

39. Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017; 176 (4): 890-901.10.1111/bjd.14964541267027518205 Search in Google Scholar

40. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172 (2): 484-493.10.1111/bjd.1334825132411 Search in Google Scholar

41. Grace E, Goldblum O, Renda L, et al. Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatol Ther (Heidelb). 2020; 10 (1): 99-106.10.1007/s13555-019-00341-2699457531734937 Search in Google Scholar

42. Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-tosevere palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020; 182 (4): 889-899.10.1111/bjd.1833131286480 Search in Google Scholar

43. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderateto-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013; 168 (2): 412-421.10.1111/bjd.1211023106107 Search in Google Scholar

44. Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019; 2019: 2546161.10.1155/2019/2546161675490431583255 Search in Google Scholar

45. Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019; 81 (2): 427-432.10.1016/j.jaad.2019.02.06230872150 Search in Google Scholar

46. Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020; 34 (6): 1151-1160.10.1111/jdv.1607331721310 Search in Google Scholar

47. Kim HJ, Lebwohl MG. Biologics and Psoriasis:The Beat Goes On. Dermatol Clin. 2019; 37 (1): 29-36.10.1016/j.det.2018.07.00430466686 Search in Google Scholar

48. Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018; 45 (3): 279-286.10.1111/1346-8138.1409629226369 Search in Google Scholar

49. Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020; 34 (2): 293-300.10.1111/jdv.1587831419355 Search in Google Scholar

50. Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford). 2018; 57 (3): 563-571.10.1093/rheumatology/kex45229244162 Search in Google Scholar

51. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017; 31 (4): 299-316.10.1007/s40259-017-0231-8554881428612180 Search in Google Scholar

52. Topaloğlu Demir F, Özkök Akbulut T, Kıvanç Altunay İ, et al. Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study. Dermatol Ther. 2020; 33(6): e14216.10.1111/dth.1421632827159 Search in Google Scholar